Core Viewpoint - Reborn Bio-B (06938) has seen a stock increase of over 5%, currently trading at 72.45 HKD, following the announcement of its RBD5044 injection receiving implied approval for Phase II clinical trials from the National Medical Products Administration of China [1] Company Summary - RBD5044 is a siRNA drug targeting APOC3, a protein synthesized primarily in the liver that plays a crucial role in lipid metabolism [1] - The drug aims to address complications associated with hypertriglyceridemia, providing a treatment option for managing dyslipidemia [1] Industry Summary - The small nucleic acid drug sector is experiencing significant global growth, transitioning from technology validation to accelerated clinical realization and commercialization [1] - A total of 23 small nucleic acid drugs have been approved globally, covering various technical directions such as siRNA, ASO, and aptamers [1] - Although no products have been launched domestically, the number of research pipelines ranks second only to the United States, addressing multiple therapeutic areas including hyperlipidemia, hypertension, hepatitis B, kidney diseases, muscular diseases, and obesity [1] - Notable collaborations include over 9 billion USD in cumulative partnerships between WuXi AppTec and Novartis, and a 2 billion USD platform licensing deal between Reborn Bio and Boehringer Ingelheim [1] - Traditional pharmaceutical companies like China National Pharmaceutical Group are rapidly positioning themselves through acquisitions, indicating a positive development trend in the industry [1]

Core Viewpoint - Reborn Bio-B (06938) shares rose over 5%, currently up 5.62% at HKD 72.45, with a trading volume of HKD 6.483 million, following the announcement of the II phase clinical trial approval for its self-developed RBD5044 injection by the National Medical Products Administration of China [1] Company Summary - RBD5044 is a siRNA drug targeting APOC3, a protein synthesized primarily in the liver that plays a crucial role in lipid metabolism [1] - The drug aims to address complications associated with hypertriglyceridemia, providing a treatment option for managing dyslipidemia [1] Industry Summary - According to Guosheng Securities (002670), small nucleic acid drugs are entering a robust global development phase, transitioning from technical validation to clinical realization and accelerated commercialization [1] - A total of 23 small nucleic acid drugs have been approved globally, covering various technical directions such as siRNA, ASO, and aptamers [1] - Although no products have been launched domestically yet, the number of research pipelines ranks second to the U.S., covering multiple therapeutic areas including hyperlipidemia, hypertension, hepatitis B, kidney diseases, muscular diseases, and obesity [1] - Significant collaborations have emerged, such as the over USD 9 billion partnership between WuXi AppTec and Novartis, and a USD 2 billion platform licensing deal between Reborn Bio and Boehringer Ingelheim, indicating a positive development trend in the industry [1]

Core Viewpoint - RiboBio-B (06938) has received implied approval from the National Medical Products Administration of China for the Phase II clinical trial of its self-developed RBD5044 injection, which targets APOC3 and addresses complications related to hypertriglyceridemia [1] Group 1 - RBD5044 is a siRNA drug that specifically targets APOC3, a protein synthesized almost exclusively in the liver [1] - APOC3 plays a critical role in lipid metabolism, making RBD5044 a potential treatment option for managing dyslipidemia [1] - The drug aims to address complications associated with hypertriglyceridemia, providing a new therapeutic choice in lipid management [1]

Core Viewpoint - RBD5044, a siRNA drug targeting APOC3, has received implied approval for Phase II clinical trials from the National Medical Products Administration of China, indicating a significant step forward in the management of dyslipidemia related to hypertriglyceridemia [1] Group 1: Company Information - RBD5044 is developed by Reborn Bio-B (06938) and is designed to address complications associated with hypertriglyceridemia [1] - The drug targets APOC3, a protein synthesized primarily in the liver, which plays a crucial role in lipid metabolism [1] Group 2: Industry Context - The approval of RBD5044 represents a potential new treatment option for managing lipid disorders, highlighting advancements in the field of lipid metabolism therapies [1]

Core Viewpoint - Reborn Bio-B (06938.HK) has received implied approval from the National Medical Products Administration of China for the Phase II clinical trial of its self-developed RBD5044 injection, a targeted siRNA drug aimed at APOC3 [1] Group 1: Product Development - RBD5044 is designed to target APOC3, a protein primarily synthesized in the liver that plays a crucial role in lipid metabolism [1] - The drug addresses complications associated with hypertriglyceridemia, providing a treatment option for managing dyslipidemia [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不對因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 蘇州瑞博生物技術股份有限公司 （於中華人民共和國註冊成立的股份有限公司） Suzhou Ribo Life Science Co., Ltd. （股份代號：6938） 自願公告 RBD5044於中國的II期臨床試驗默示許可 本公告由蘇州瑞博生物技術股份有限公司（「本公司」，連同其子公司統稱「本集 團」）自願作出，旨在向本公司股東（「股東」）及潛在投資者提供本集團研發進展的 最新情況。 本公司董事（「董事」）會（「董事會」）欣然宣佈，本集團自主研發的RBD5044注射 液已獲中國國家藥品監督管理局的II期臨床試驗默示許可。 香港，2026年1月23日 截至本公告日期，執行董事為梁子才博士、甘黎明博士及張鴻雁博士，非執行董 事為戚飛博士、李東方先生及李宇輝先生，及獨立非執行董事為宇學峰博士、馬 朝松先生及王瑞平先生。 RBD5044是一款靶向APOC3的siRNA藥物。APOC3是一種幾乎只在肝臟中合成 的蛋 ...